The dual role of inflammation in colon carcinogenesis

International Journal of Molecular Sciences

Volumn 13, Issue 9, 2012, Pages 11071-11084

  Monteleone, Giovanni ^a   Pallone, Francesco ^a   Stolfi, Carmine ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Colitis associated colon cancer; IBD; IL 17; IL 21; IL 6; Inflammation; T cells; Tumor immunosurveillance; Ulcerative colitis

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

CANCER GROWTH; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL INFILTRATION; COLON CARCINOGENESIS; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENTERITIS; HUMAN; IMMUNOCOMPETENT CELL; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; CD8+ T LYMPHOCYTE; CELL TRANSFORMATION; COLON; COLON TUMOR; IMMUNOLOGY; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; METABOLISM; PATHOLOGY; RISK;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; COLON; COLONIC NEOPLASMS; CYTOKINES; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; RISK;

EID: 84866936329     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms130911071     Document Type: Review

References (81)

1. Kundu, J.K.; Surh, Y.J. Inflammation: Gearing the journey to cancer. Mutat. Res. 2008, 659, 15-30.
2. Bernstein, C.N.; Blanchard, J.F.; Kliewer, E.; Wajda, A. Cancer risk in patients with inflammatory bowel disease: A population-based study. Cancer 2001, 91, 854-862.
3. Eaden, J.A.; Abrams, K.R.; Mayberry, J.F. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut 2001, 48, 526-535.
4. Ekbom, A.; Helmick, C.; Zack, M.; Adami, H.O. Ulcerative colitis and colorectal cancer. A population-based study. N. Engl. J. Med. 1990, 323, 1228-1233.
5. Rizzo, A.; Pallone, F.; Monteleone, G.; Fantini, M.C. Intestinal inflammation and colorectal cancer: A double-edged sword? World J. Gastroenterol. 2011, 17, 3092-3100.
6. Erreni, M.; Mantovani, A.; Allavena, P. Tumor-associated macrophages (tam) and inflammation in colorectal cancer. Cancer Microenviron. 2011, 4, 141-154.
7. Mueller, M.M.; Fusenig, N.E. Friends or foes-Bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 2004, 4, 839-849.
8. Terzic, J.; Grivennikov, S.; Karin, E.; Karin, M. Inflammation and colon cancer. Gastroenterology 2010, 138, 2101-2114.
9. Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, inflammation, and cancer. Cell 2010, 140, 883-899.
10. Galon, J.; Costes, A.; Sanchez-Cabo, F.; Kirilovsky, A.; Mlecnik, B.; Lagorce-Pages, C.; Tosolini, M.; Camus, M.; Berger, A.; Wind, P.; et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313, 1960-1964.
11. Osawa, E.; Nakajima, A.; Fujisawa, T.; Kawamura, Y.I.; Toyama-Sorimachi, N.; Nakagama, H.; Dohi, T. Predominant t helper type 2-inflammatory responses promote murine colon cancers. Int. J. Cancer 2006, 118, 2232-2236.
12. Kettunen, H.L.; Kettunen, A.S.; Rautonen, N.E. Intestinal immune responses in wild-type and apcmin/+ mouse, a model for colon cancer. Cancer Res. 2003, 63, 5136-5142.
13. Shibata, M.; Nezu, T.; Kanou, H.; Abe, H.; Takekawa, M.; Fukuzawa, M. Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J. Clin. Gastroenterol. 2002, 34, 416-420.
14. Endo, Y.; Marusawa, H.; Kou, T.; Nakase, H.; Fujii, S.; Fujimori, T.; Kinoshita, K.; Honjo, T.; Chiba, T. Activation-induced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers. Gastroenterology 2008, 135, 889-898.
15. Dunn, G.P.; Koebel, C.M.; Schreiber, R.D. Interferons, immunity and cancer immunoediting. Nat. Rev. 2006, 6, 836-848.
16. Swann, J.B.; Smyth, M.J. Immune surveillance of tumors. J. Clin. Investig. 2007, 117, 1137-1146.
17. Canavan, C.; Abrams, K.R.; Mayberry, J. Meta-analysis: Colorectal and small bowel cancer risk in patients with crohn's disease. Aliment. Pharmacol. Ther. 2006, 23, 1097-1104.
18. Monteleone, I.; Sarra, M.; Pallone, F.; Monteleone, G. Th17-related cytokines in inflammatory bowel diseases: Friends or foes? Curr. Mol. Med. 2012, 12, 592-597.
19. Dunn, G.P.; Old, L.J.; Schreiber, R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21, 137-148.
20. Tannenbaum, C.S.; Hamilton, T.A. Immune-inflammatory mechanisms in ifngamma-mediated anti-tumor activity. Semin. Cancer Biol. 2000, 10, 113-123.
21. Talmadge, J.E.; Donkor, M.; Scholar, E. Inflammatory cell infiltration of tumors: Jekyll or hyde. Cancer Metastasis Rev. 2007, 26, 373-400.
22. Naito, Y.; Saito, K.; Shiiba, K.; Ohuchi, A.; Saigenji, K.; Nagura, H.; Ohtani, H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998, 58, 3491-3494.
23. Michael-Robinson, J.M.; Pandeya, N.; Walsh, M.D.; Biemer-Huttmann, A.E.; Eri, R.D.; Buttenshaw, R.L.; Lincoln, D.; Clouston, A.D.; Jass, J.R.; Radford-Smith, G.L. Characterization of tumour-infiltrating lymphocytes and apoptosis in colitis-associated neoplasia: Comparison with sporadic colorectal cancer. J. Pathol. 2006, 208, 381-387.
24. Muller, S.; Lory, J.; Corazza, N.; Griffiths, G.M.; Z'Graggen, K.; Mazzucchelli, L.; Kappeler, A.; Mueller, C. Activated CD4+ and CD8+ cytotoxic cells are present in increased numbers in the intestinal mucosa from patients with active inflammatory bowel disease. Am. J. Pathol. 1998, 152, 261-268.
25. Waldner, M.J.; Wirtz, S.; Becker, C.; Seidel, D.; Tubbe, I.; Cappel, K.; Hahnel, P.S.; Galle, P.R.; Schuler, M.; Neurath, M.F. Perforin deficiency attenuates inflammation and tumor growth in colitis-associated cancer. Inflamm. Bowel Dis. 2010, 16, 559-567.
26. Rizzo, A.; Waldner, M.J.; Stolfi, C.; Sarra, M.; Fina, D.; Becker, C.; Neurath, M.F.; Macdonald, T.T.; Pallone, F.; Monteleone, G., et al. Smad7 expression in T cells prevents colitis-associated cancer. Cancer Res. 2011, 71, 7423-7432.
27. Berzofsky, J.A.; Terabe, M. The contrasting roles of NKT cells in tumor immunity. Curr. Mol. Med. 2009, 9, 667-672.
28. Kitamura, H.; Iwakabe, K.; Yahata, T.; Nishimura, S.; Ohta, A.; Ohmi, Y.; Sato, M.; Takeda, K.; Okumura, K.; van Kaer, L. et al. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 1999, 189, 1121-1128.
29. Fuss, I.J.; Heller, F.; Boirivant, M.; Leon, F.; Yoshida, M.; Fichtner-Feigl, S.; Yang, Z.; Exley, M.; Kitani, A.; Blumberg, R.S., et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Investig. 2004, 113, 1490-1497.
30. Liao, C.M.; Zimmer, M.I.; Shanmuganad, S.; Yu, H.T.; Cardell, S.L.; Wang, C.R. Dysregulation of cd1d-restricted type ii natural killer t cells leads to spontaneous development of colitis in mice. Gastroenterology 2012, 142, 326-334.
31. Thompson, C.; Powrie, F. Regulatory T cells. Curr. Opin. Pharmacol. 2004, 4, 408-414.
32. Deleeuw, R.J.; Kost, S.E.; Kakal, J.A.; Nelson, B.H. The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in cancer: A critical review of the literature. Clin. Cancer Res. 2012, 18, 3022-3029.
33. Ladoire, S.; Martin, F.; Ghiringhelli, F. Prognostic role of Foxp3+ regulatory T cells infiltrating human carcinomas: The paradox of colorectal cancer. Cancer Immunol. Immunother. 2011, 60, 909-918.
34. Erdman, S.E.; Sohn, J.J.; Rao, V.P.; Nambiar, P.R.; Ge, Z.; Fox, J.G.; Schauer, D.B. CD4+ CD25+ regulatory lymphocytes induce regression of intestinal tumors in Apcmin/+ mice. Cancer Res. 2005, 65, 3998-4004.
35. Sugai, M.; Aoki, K.; Osato, M.; Nambu, Y.; Ito, K.; Taketo, M.M.; Shimizu, A. Runx3 is required for full activation of regulatory T cells to prevent colitis-associated tumor formation. J. Immunol. 2011, 186, 6515-6520.
36. Fukata, M.; Abreu, M.T. What are Toll-like receptors and what role may they have in IBD? Inflamm. Bowel Dis. 2008, 14, S90-S92.
37. Cario, E.; Podolsky, D.K. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect. Immun. 2000, 68, 7010-7017.
38. Fukata, M.; Abreu, M.T. Role of Toll-like receptors in gastrointestinal malignancies. Oncogene 2008, 27, 234-243.
39. Fukata, M.; Chen, A.; Vamadevan, A.S.; Cohen, J.; Breglio, K.; Krishnareddy, S.; Hsu, D.; Xu, R.; Harpaz, N.; Dannenberg, A.J., et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007, 133, 1869-1881.
40. Fukata, M.; Hernandez, Y.; Conduah, D.; Cohen, J.; Chen, A.; Breglio, K.; Goo, T.; Hsu, D.; Xu, R.; Abreu, M.T. Innate immune signaling by toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm. Bowel Dis. 2009, 15, 997-1006.
41. Salcedo, R.; Worschech, A.; Cardone, M.; Jones, Y.; Gyulai, Z.; Dai, R.M.; Wang, E.; Ma, W.; Haines, D.; O'HUigin, C., et al. Myd88-mediated signaling prevents development ofadenocarcinomas of the colon: Role of interleukin 18. J. Exp. Med. 2010, 207, 1625-1636.
42. Rakoff-Nahoum, S.; Medzhitov, R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein Myd88. Science 2007, 317, 124-127.
43. Uronis, J.M.; Muhlbauer, M.; Herfarth, H.H.; Rubinas, T.C.; Jones, G.S.; Jobin, C. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One 2009, 4, e6026.
44. Sica, A. Role of tumour-associated macrophages in cancer-related inflammation. Exp. Oncol. 2010, 32, 153-158.
45. Allavena, P.; Sica, A.; Garlanda, C.; Mantovani, A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol. Rev. 2008, 222, 155-161.
46. Hayakawa, Y.; Hirata, Y.; Nakagawa, H.; Sakamoto, K.; Hikiba, Y.; Otsuka, M.; Ijichi, H.; Ikenoue, T.; Tateishi, K.; Akanuma, M., et al. Apoptosis signal-regulating kinase 1 regulates colitis and colitis-associated tumorigenesis by the innate immune responses. Gastroenterology 2010, 138, 1055-1067.
47. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature 2008, 454, 436-444.
48. Bertazza, L.; Mocellin, S. The dual role of tumor necrosis factor (TNF) in cancer biology. Curr. Med. Chem. 2010, 17, 3337-3352.
49. Rutgeerts, P.; van Assche, G.; Vermeire, S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004, 126, 1593-1610.
50. Popivanova, B.K.; Kitamura, K.; Wu, Y.; Kondo, T.; Kagaya, T.; Kaneko, S.; Oshima, M.; Fujii, C.; Mukaida, N. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Investig. 2008, 118, 560-570.
51. Vallabhapurapu, S.; Karin, M. Regulation and function of NF-kappab transcription factors in the immune system. Annu. Rev. Immunol. 2009, 27, 693-733.
52. Greten, F.R.; Eckmann, L.; Greten, T.F.; Park, J.M.; Li, Z.W.; Egan, L.J.; Kagnoff, M.F.; Karin, M. Ikkbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118, 285-296.
53. Mangan, P.R.; Harrington, L.E.; O'Quinn, D.B.; Helms, W.S.; Bullard, D.C.; Elson, C.O.; Hatton, R.D.; Wahl, S.M.; Schoeb, T.R.; Weaver, C.T. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 441, 231-234.
54. Rose-John, S.; Scheller, J.; Elson, G.; Jones, S.A. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: Role in inflammation and cancer. J. Leukoc. Biol. 2006, 80, 227-236.
55. Bollrath, J.; Phesse, T.J.; von Burstin, V.A.; Putoczki, T.; Bennecke, M.; Bateman, T.; Nebelsiek, T.; Lundgren-May, T.; Canli, O.; Schwitalla, S., et al. Gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15, 91-102.
56. Grivennikov, S.; Karin, E.; Terzic, J.; Mucida, D.; Yu, G.Y.; Vallabhapurapu, S.; Scheller, J.; Rose-John, S.; Cheroutre, H.; Eckmann, L., et al. Il-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15, 103-113.
57. Musteanu, M.; Blaas, L.; Mair, M.; Schlederer, M.; Bilban, M.; Tauber, S.; Esterbauer, H.; Mueller, M.; Casanova, E.; Kenner, L., et al. Stat3 is a negative regulator of intestinal tumor progression in Apc(min) mice. Gastroenterology 2010, 138, 1003-1011.
58. Lee, J.; Kim, J.C.; Lee, S.E.; Quinley, C.; Kim, H.; Herdman, S.; Corr, M.; Raz, E. Signal transducer and activator of transcription 3 (Stat3) protein suppresses adenoma-to-carcinoma transition in Apcmin/+ mice via regulation of Snail-1 (Snai) protein stability. J. Biol. Chem. 2012, 287, 18182-18189.
59. Hyams, J.S.; Fitzgerald, J.E.; Treem, W.R.; Wyzga, N.; Kreutzer, D.L. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology 1993, 104, 1285-1292.
60. Atreya, R.; Mudter, J.; Finotto, S.; Mullberg, J.; Jostock, T.; Wirtz, S.; Schutz, M.; Bartsch, B.; Holtmann, M.; Becker, C.; et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in crohn disease and experimental colitis in vivo. Nat. Med. 2000, 6, 583-588.
61. Becker, C.; Fantini, M.C.; Schramm, C.; Lehr, H.A.; Wirtz, S.; Nikolaev, A.; Burg, J.; Strand, S.; Kiesslich, R.; Huber, S.; et al. Tgf-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004, 21, 491-501.
62. Matsumoto, S.; Hara, T.; Mitsuyama, K.; Yamamoto, M.; Tsuruta, O.; Sata, M.; Scheller, J.; Rose-John, S.; Kado, S.; Takada, T. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J. Immunol. 2010, 184, 1543-1551.
63. Li, Y.; de Haar, C.; Chen, M.; Deuring, J.; Gerrits, M.M.; Smits, R.; Xia, B.; Kuipers, E.J.; van der Woude, C.J. Disease-related expression of the IL6/Stat3/Socs3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 2010, 59, 227-235.
64. Rigby, R.J.; Simmons, J.G.; Greenhalgh, C.J.; Alexander, W.S.; Lund, P.K. Suppressor of cytokine signaling 3 (Socs3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon. Oncogene 2007, 26, 4833-4841.
65. Gerlach, K.; Daniel, C.; Lehr, H.A.; Nikolaev, A.; Gerlach, T.; Atreya, R.; Rose-John, S.; Neurath, M.F.; Weigmann, B. Transcription factor NFATc2 controls the emergence of colon cancer associated with IL-6-dependent colitis. Cancer Res. 2012, 72, 4340-4350.
66. Curtis, M.M.; Way, S.S. Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology 2009, 126, 177-185.
67. Zhu, S.; Qian, Y. IL-17/IL-17 receptor system in autoimmune disease: Mechanisms and therapeutic potential. Clin. Sci. 2012, 122, 487-511.
68. Hueber, W.; Sands, B.E.; Lewitzky, S.; Vandemeulebroecke, M.; Reinisch, W.; Higgins, P.D.; Wehkamp, J.; Feagan, B.G.; Yao, M.D.; Karczewski, M., et al. Secukinumab, a human anti-IL-17a monoclonal antibody, for moderate to severe crohn's disease: Unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012, doi:10.1136/gutjnl-2011-301668.
69. Leppkes, M.; Becker, C.; Ivanov, I.I.; Hirth, S.; Wirtz, S.; Neufert, C.; Pouly, S.; Murphy, A.J.; Valenzuela, D.M.; Yancopoulos, G.D., et al. Rorgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17a and IL-17f. Gastroenterology 2009, 136, 257-267.
70. Muranski, P.; Boni, A.; Antony, P.A.; Cassard, L.; Irvine, K.R.; Kaiser, A.; Paulos, C.M.; Palmer, D.C.; Touloukian, C.E.; Ptak, K., et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008, 112, 362-373.
71. Benchetrit, F.; Ciree, A.; Vives, V.; Warnier, G.; Gey, A.; Sautes-Fridman, C.; Fossiez, F.; Haicheur, N.; Fridman, W.H.; Tartour, E. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002, 99, 2114-2121.
72. Kryczek, I.; Wei, S.; Szeliga, W.; Vatan, L.; Zou, W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009, 114, 357-359.
73. Wu, S.; Rhee, K.J.; Albesiano, E.; Rabizadeh, S.; Wu, X.; Yen, H.R.; Huso, D.L.; Brancati, F.L.; Wick, E.; McAllister, F., et al. A human colonic commensal promotes colon tumorigenesis via activation of t helper type 17 T cell responses. Nat. Med. 2009, 15, 1016-1022.
74. Chae, W.J.; Gibson, T.F.; Zelterman, D.; Hao, L.; Henegariu, O.; Bothwell, A.L. Ablation of IL-17a abrogates progression of spontaneous intestinal tumorigenesis. Proc. Natl. Acad. Sci. USA 2010, 107, 5540-5544.
75. Hyun, Y.S.; Han, D.S.; Lee, A.R.; Eun, C.S.; Youn, J.; Kim, H.Y. Role of IL-17a in the development of colitis-associated cancer. Carcinogenesis 2012, 33, 931-936.
76. Monteleone, G.; Pallone, F.; Macdonald, T.T. Interleukin-21 as a new therapeutic target for immune-mediated diseases. Trends Pharmacol. Sci. 2009, 30, 441-447.
77. Sondergaard, H.; Skak, K. IL-21: Roles in immunopathology and cancer therapy. Tissue antigens 2009, 74, 467-479.
78. Monteleone, G.; Monteleone, I.; Fina, D.; Vavassori, P.; del Vecchio Blanco, G.; Caruso, R.; Tersigni, R.; Alessandroni, L.; Biancone, L.; Naccari, G.C., et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in crohn's disease. Gastroenterology 2005, 128, 687-694.
79. Fina, D.; Sarra, M.; Fantini, M.C.; Rizzo, A.; Caruso, R.; Caprioli, F.; Stolfi, C.; Cardolini, I.; Dottori, M.; Boirivant, M. et al. Regulation of gut inflammation and Th17 cell response by interleukin-21. Gastroenterology 2008, 134, 1038-1048.
80. Stolfi, C.; Rizzo, A.; Franze, E.; Rotondi, A.; Fantini, M.C.; Sarra, M.; Caruso, R.; Monteleone, I.; Sileri, P.; Franceschilli, L. et al. Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J. Exp. Med. 2011, 208, 2279-2290.
81. Jauch, D.; Martin, M.; Schiechl, G.; Kesselring, R.; Schlitt, H.J.; Geissler, E.K.; Fichtner-Feigl, S. Interleukin 21 controls tumour growth and tumour immunosurveillance in colitis-associated tumorigenesis in mice. Gut 2011, 60, 1678-1686.